Table 1.
Kinase inhibitors with anti-NAK activity used in this study. Dissociation constant (Kd), enzymatic activity (IC50), percent binding of control (% of control) values measured in vitro on the four NAKs and NanoBRET GAK IC50 values measured in cells of the indicated kinase inhibitors. The source of KINOMEscan data (if available) and other targets of these compounds are also shown. Kd, IC50, and % of control are shown as *, ** and *** respectively. ^ represents data obtained in this study.
| Compound | Status |
|
NanoBRET GAK IC50 (nM) | Reference | Kinome | Other targets | |||
|---|---|---|---|---|---|---|---|---|---|
| AAK1 | BIKE | GAK | STK16 | ||||||
| (5Z)-7- Oxozeaenol | Investigational | 13%*** | 3.8%*** | 10%*** | 100%*** | NA | Pu et al.,2020 | ID: 20211 | TAK1 (8 nM), VEGFR2 (52 nM), ERK2 (80 nM) |
| Sunitinib | Approved (cancer) | 11 nM* | 5.5 nM* | 20 nM* | 250 nM* | NA | Davis et al.,2011 | Davis et al.,2011 | VEGFR2 (80 nM), PDGFRβ (2 nM), FLT3, KIT, PDGFRα |
| Erlotinib | Approved (cancer) | 1200 nM* | 1200 nM* | 3 nM* | >9000 nM* | 910 nM | Asquith et al., 2019a, Asquith et al., 2019b | Davis et al.,2011 | ErbB1 (0.7 nM), STK10 (19 nM), YSK4 (25 nM), SLK (26 nM) |
| Gefitinib | Approved (cancer) | >10,000 nM**a | >10,000 nM**a | 13 nM* | NA | 420 nM | Asquith et al., 2019a, Asquith et al., 2019b | Davis et al.,2011 | EGFR |
| Baricitinib | Approved (RA) | 17 nM* | 40 nM* | 134 nM∗ | 69 nM* | NA | Stebbing et al.,2021 | Klaeger et al.,2017 | JAK1 (5.9 nM), JAK2 (5.7 nM), ROCK1/2, TYK2 (53 nM), CAMK2A, MAP3K2, PRPF4B |
| RMC-76 | Experimental | 4 nM** | 3.8 nM*a | 280 nM*a | NA | NA | Figure S1 | NA | CDC42BPB, PRKD3, CLK1, CLK4, ULK3, MINK1 |
| RMC-242 | Experimental | 4100 nM*a | >15000 n M*a | 12 nM** | NA | 78 nMa | Martinez-Gualda et al.,2021 | NA | NA |
| SGC-GAK-1 | Experimental | NA 86%*** |
NA 92%*** |
2 nM* 9.7%*** |
NA 84%*** |
48 nM | Asquith et al., 2019a, Asquith et al., 2019b | Asquith et al., 2019a, Asquith et al., 2019b | RIPK2 (110 nM), ADCK3 (190 nM), NLK (520 nM) |
| STK-16-1N-1 | Experimental | NA 13%*** |
NA 9.5%*** |
NA 46%*** |
295 nM** 0.65%*** |
NA | Liu et al., 2016 | Liu et al.,2016 | PI3Kδ (856 nM), PI3Kγ (867 nM) |
Data obtained in this study, RA= Rheumatoid Arthritis